Barclays
STLN

Barclays’s Starling Oncology STLN Stock Holding History

Barclays’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$184K Buy
33,929
+18,753
+124% +$78.8K ﹤0.01% 3764
2026
Q1 		$46.6K Sell
15,176
-91,276
-86% -$280K ﹤0.01% 4345
2025
Q4 		$379K Buy
106,452
+20,605
+24% +$76.4K ﹤0.01% 4010
2025
Q3 		$300K Sell
85,847
-17,823
-17% -$61.1K ﹤0.01% 4102
2025
Q2 		$213K Buy
+103,670
New +$259K ﹤0.01% 4233
2023
Q2 		– Sell
-19,840
Closed -$13.4K – 5075
2023
Q1 		$13.4K Buy
19,840
+10,497
+112% +$13.4K ﹤0.01% 4710
2022
Q4 		$15.4K Buy
9,343
+7,868
+533% +$22.1K ﹤0.01% 4861
2022
Q3 		$7K Buy
1,475
+534
+57% +$3.14K ﹤0.01% 4429
2022
Q2 		$5K Buy
+941
New +$6.85K ﹤0.01% 4789

Other funds holding STLN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Barclays's STLN Position: Q2 2026 in Review

Barclays increased its Starling Oncology (STLN) stake by 124% in Q2 2026, buying an estimated $78.8K and bringing the position to 33,929 shares worth $184K. The position accounts for ﹤0.01% of the portfolio, ranked #3764.

Barclays first reported a position in STLN in Q2 2022 and has held it in 9 quarters since. The position peaked at $379K in Q4 2025. 119 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

  • Barclays held 33,929 shares of Starling Oncology worth $184K as of Q2 2026.
  • Barclays bought 18,753 Starling Oncology shares in Q2 2026, an estimated $78.8K.
  • Starling Oncology made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3764 holding.
  • Barclays first reported a position in Starling Oncology in Q2 2022 and has held it in 9 quarters since.
  • Barclays's Starling Oncology position peaked at $379K in Q4 2025.
  • 119 funds tracked by Wall St. Rank held Starling Oncology as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.